Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03592641 · ClinicalTrials.gov registry record · Phase 2
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03592641: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT03592641 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03592641, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This phase II trial studies how well savolitinib works in treating patients with MET amplified colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Savolitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Savolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-07-25 |
| Est. Completion | 2021-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03592641
The ClinicalTrials.gov registry entry for NCT03592641 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Savolitinib is the first listed.
NCT03592641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03592641 about?
NCT03592641 is a clinical study titled "Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer". This phase II trial studies how well savolitinib works in treating patients with MET amplified colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Savolitinib may stop the growth of tumor cells by blocking some of the enzymes nee...
What is the current status of trial NCT03592641?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2019-07-25. Estimated completion is 2021-12-30.
What interventions are being tested in trial NCT03592641?
The interventions under investigation include: Savolitinib (DRUG).
Who is sponsoring clinical trial NCT03592641?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.